GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...

Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, said: “The SURPASS-CVOT results show ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

Eli Lilly and Company (NYSE:LLY) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Eli Lilly and Company ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION).

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...

Two new JAMA Network Open studies link popular diabetes and weight loss drugs, including Ozempic and Mounjaro, to a slightly ...

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

For Lilly, orforglipron could also complement its injectable formulation of tirzepatide for diabetes – Mounjaro – and injectable GLP-1 agonist Trulicity (dulaglutide).

There was also an 8% lower risk of death from any cause among patients taking GLP-1 drugs like Novo Nordisk's Ozempic (semaglutide) and Eli Lilly's Trulicity (dulaglutide) for diabetes and Novo ...